Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omega Therapeutics (OMGA)
NASDAQ:OMGA
Omega Therapeutics (OMGA) Stock Price & Analysis
331 Followers
OMGA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $6.30
Previous Close$2.04
Volume336.04K
Average Volume (3M)500.77K
Market Cap
$112.52M
Enterprise Value$167.49M
Total Cash (Recent Filing)$73.43M
Total Debt (Recent Filing)$128.40M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 01, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding55,154,985
10 Day Avg. Volume546,947
30 Day Avg. Volume500,775
Standard Deviation0.33
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.31
Price to Sales (P/S)43.32
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue54.12
Enterprise Value/Gross Profit54.13
Enterprise Value/Ebitda-3.81
Forecast
1Y Price Target
$10.33Price Target Upside429.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Omega Therapeutics News
PremiumCompany Announcements
Omega Therapeutics Appoints New Chief Business Officer
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsOTX-2002 demonstrated an 80% disease control rate (DCR) in HCC patients and 40% in non-HCC solid tumor patients.
Financial PerformanceOmega reported a net loss of $0.37 per share, narrower than the prior estimate of a net loss of $0.46 per share; the difference can predominantly be attributed to lower than expected operating expenses.
Funding And PartnershipsManagement now projects that its cash, which includes a $5.1 million upfront payment from Novo Nordisk, is sufficient to fund operations into 1Q25.
Bears Say
Financial PerformanceThe company ended the year with cash, equivalents, and marketable securities of $73.4 million compared to $125 million at the end of 2022.
Operational ChangesThe company has implemented a strategic prioritization and 35% headcount reduction in order to reduce its operating expense.
Quarterly PerformanceThe company ended the quarter with cash, equivalents, and marketable securities of $60.0 million compared to $68.4 million at the end of the previous quarter.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OMGA FAQ
What was Omega Therapeutics’s price range in the past 12 months?
Omega Therapeutics lowest stock price was $1.30 and its highest was $6.30 in the past 12 months.
What is Omega Therapeutics’s market cap?
Currently, no data Available
When is Omega Therapeutics’s upcoming earnings report date?
Omega Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 14 days.
How were Omega Therapeutics’s earnings last quarter?
Omega Therapeutics released its earnings results on May 06, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.027.
Is Omega Therapeutics overvalued?
According to Wall Street analysts Omega Therapeutics’s price is currently Undervalued.
Does Omega Therapeutics pay dividends?
Omega Therapeutics does not currently pay dividends.
What is Omega Therapeutics’s EPS estimate?
Omega Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Omega Therapeutics have?
Omega Therapeutics has 55,154,984 shares outstanding.
What happened to Omega Therapeutics’s price movement after its last earnings report?
Omega Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -11.628%.
Which hedge fund is a major shareholder of Omega Therapeutics?
Among the largest hedge funds holding Omega Therapeutics’s share is Flagship Pioneering Inc.. It holds Omega Therapeutics’s shares valued at 107M.
---
Omega Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (429.74% Upside)
$10.33 (429.74% Upside)
Blogger Sentiment
Bullish
OMGA Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.23%
12-Months-Change
Fundamentals
Return on Equity
-112.29%
Trailing 12-Months
Asset Growth
17.51%
Trailing 12-Months
Company Description
Omega Therapeutics
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease.
---
OMGA Stock 12 Month Forecast
Average Price Target
$10.33
▲(429.74% Upside)
Technical Analysis
Voyager Therapeutics
―
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Sarepta Therapeutics
―
Best Analysts Covering OMGA
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
+8.85%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +8.85% per trade.
---